WG
LFCR icon

Winton Group’s Lifecore Biomedical LFCR Stock Holding History

Winton Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-68,695
Closed -$668K – 1425
2020
Q3 		$668K Buy
68,695
+14,533
+27% +$138K 0.02% 990
2020
Q2 		$431K Buy
54,162
+28,062
+108% +$290K 0.01% 1215
2020
Q1 		$227K Sell
26,100
-12,590
-33% -$131K 0.01% 1227
2019
Q4 		$438K Sell
38,690
-43,168
-53% -$459K 0.01% 1280
2019
Q3 		$890K Buy
+81,858
New +$891K 0.01% 890

Other funds holding LFCR

LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Winton Group's LFCR Position: Q4 2020 in Review

Winton Group sold out of Lifecore Biomedical (LFCR) in Q4 2020, closing a stake of 68,695 shares — an estimated $668K sold.

Winton Group first reported a position in LFCR in Q3 2019 and held it in 5 quarters. The position peaked at $890K in Q3 2019. 96 funds tracked by Wall St. Rank hold LFCR as of Q4 2020.

  • Winton Group reported no remaining Lifecore Biomedical position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 68,695 Lifecore Biomedical shares in Q4 2020, an estimated $668K.
  • Winton Group first reported a position in Lifecore Biomedical in Q3 2019 and held it in 5 quarters.
  • Winton Group's Lifecore Biomedical position peaked at $890K in Q3 2019.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.